New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback